What GLP-1s actually cost, and the levers that lower it

The honest sticker picture

List prices in the US for the branded weekly injectables have hovered roughly in the $1,000 to $1,350 per month range, with daily liraglutide below that and its generics lower still. Two things make the sticker misleading in both directions: insured patients with coverage often pay far less, and uninsured patients paying cash have manufacturer channels well under list. Numbers move frequently, so treat anything you read (including this) as a starting point to verify, not a quote.

The levers, strongest first

1. Insurance formulary, and the prior authorization fight

Coverage for weight-management GLP-1s varies wildly by plan and employer, and where it exists it usually arrives with prior authorization: documented BMI, comorbidities, sometimes previous attempts. This is paperwork your prescriber's office fights routinely; your job is supplying the documentation, which is one more place a clean weight-and-history log pays for itself. Denials get appealed, and appeals succeed often enough to be worth it. Medicare's rules differ (historically excluding weight-loss indications while covering diabetes ones, with sleep apnea indications opening doors); check current status for your plan year.

2. Manufacturer self-pay programs

Both major manufacturers run direct-to-patient channels selling authentic product at self-pay prices commonly in the $350 to $650 a month range depending on product and dose, sometimes with lower entry doses cheaper. If you are uninsured or your plan excludes weight loss, these channels (not gray-market websites) are the legitimate cash path. Savings cards for the commercially insured stack on top where eligible.

3. Product and dose strategy

Formularies often prefer one molecule: taking the covered drug at 90% of the ideal usually beats paying cash for the perfect one. Maintenance dose matters too: staying at an effective middle dose rather than the maximum is legitimate medicine and, in some cash channels, cheaper. Both are prescriber conversations; the titration post covers the dose logic.

4. The pathways to avoid

Post-shortage-era compounded bargains from unverifiable sources, imported vials, and no-screening telehealth mills: the savings are real until the product is not. The compounded post maps what remains legitimate there.

Budgeting for the real timeline

This is a months-to-years treatment, so the monthly number matters less than the sustainable number: a plan you can hold for eighteen months beats a stretch you abandon at month four (and abandonment has its own costs; see weight regain). Factor the checkpoint structure in: if a three-month trial at a covered or self-pay dose shows real response, escalating spend gets easier to justify; if not, you have spent the minimum to learn it. Log spend alongside results in DoseLog's notes if it helps the math stay honest.